What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG)

Rheumatology International

Volumn 30, Issue 9, 2010, Pages 1205-1210

  Fan, Xiangning ^a   Pope, Janet ^a   Baron, Murray ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Activity; Canadian Scleroderma Research Group (CSRG); Correlation; Damage; Severity; Systemic sclerosis

Indexed keywords

ADULT; ARTICLE; CANADA; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC SCLEROSIS; TISSUE INJURY; AGED; COHORT ANALYSIS; LOCALIZED SCLERODERMA; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; POPULATION GROUP; RESEARCH; TREATMENT OUTCOME;

ADULT; AGED; CANADA; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POPULATION GROUPS; RESEARCH; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 77954425697     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1129-7     Document Type: Article

References (34)

1. J Varga D Abraham 2007 Systemic sclerosis: a prototypic multisystem fibrotic disorder J Clin Invest 117 3 557 567 10.1172/JCI31139 1:CAS:528:DC%2BD2sXis12htrw%3D 17332883 (Pubitemid 46348510)
2. EC LeRoy C Black R Fleischmajer, et al. 1988 Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J Rheumatol 15 2 202 205 1:STN:280:DyaL1c3gtVWnsg%3D%3D 3361530
3. DP Symmons 1995 Disease assessment indices: activity, damage and severity Baillieres Clin Rheumatol 9 267 285 10.1016/S0950-3579(05)80190-6 1:STN:280:DyaK2MzosFWjtQ%3D%3D 7656340
4. TA Medsger Jr 2000 Assessment of damage and activity in systemic sclerosis Curr Opin Rheumatol 12 545 548 10.1097/00002281-200011000-00012 11092206
5. F Guillemin 2003 Assessment of disease activity Best Pract Res Clin Rheumatol 17 415 426 10.1016/S1521-6942(03)00026-3 12787510
6. MC Vonk FHJ van den Hoogen PLCM van Riel G Valentini 2007 What does the clinician need to improve patient care in systemic sclerosis? Ann Rheum Dis 66 1129 1131 10.1136/ard.2007.073957 17693603 (Pubitemid 47309725)
7. M Hudson R Steele M Baron 2007 Update on indices of disease activity in systemic sclerosis Semin Arthritis Rheum 37 2 93 98 10.1016/j.semarthrit.2007. 01.005 17363039 (Pubitemid 350198580)
8. G Valentini M Matucci Cerinic 2007 Disease-specific indicators, guidelines and outcome measures in scleroderma Clin Exp Rheumatol 25 Suppl 47 S159 S162
9. J Ruof P Bruhlmann BA Michel G Stucki 1999 Development and validation of a self-administered systemic sclerosis questionnaire (SySQ) Rheumatology (Oxford) 38 535 542 10.1093/rheumatology/38.6.535 1:STN:280:DyaK1MzivVGhtg%3D%3D (Pubitemid 29504839)
10. G Valentini A Della Rossa S Bombardieri, et al. 2001 European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes Ann Rheum Dis 60 592 598 10.1136/ard.60.6.592 1:STN:280:DC%2BD3M3lt1WqsQ%3D%3D 11350848 (Pubitemid 32493986)
11. PA Merkel K Herlyn RW Martin, et al. 2002 Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon Arthritis Rheum 46 2410 2420 10.1002/art.10486 12355489
12. GP Rodnan E Lipinski J Luksick 1979 Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma Arthritis Rheum 22 130 144 10.1002/art.1780220205 1:STN:280:DyaE1M7isVantg%3D%3D 420706 (Pubitemid 9156666)
13. PJ Clements PA Lachenbruch SC Ng M Simmons M Sterz DE Furst 1990 Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis Arthritis Rheum 33 1256 1263 1:STN:280:DyaK3czlvV2itg%3D%3D 2390128
14. V Steen TA Medsger Jr 1997 The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time Arthritis Rheum 40 1984 1991 10.1002/art.1780401110 1:STN:280:DyaK1c%2FjtVeluw%3D%3D 9365087 (Pubitemid 27494658)
15. TA Medsger Jr AJ Silman VD Steen, et al. 1999 A disease severity scale for systemic sclerosis. Development and testing J Rheumatol 26 2159 2167 10529133
16. AJ Geirsson FA Wollheim A Akesson 2001 Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale Ann Rheum Dis 60 1117 1122 10.1136/ard.60.12.1117 1:STN:280: DC%2BD3MnmtlClsg%3D%3D 11709453 (Pubitemid 33099994)
17. AC Gelber FM Wigley 2002 Disease severity as a predictor of outcome in scleroderma Lancet 359 277 279 10.1016/S0140-6736(02)07535-9 11830191 (Pubitemid 34119288)
18. T Arkachaisri S Pino 2008 Localized scleroderma severity index and global assessments: a pilot study of outcome instruments J Rheumatol 35 650 657 10.3899/jrheum.080098 18322985
19. World Health Organization Disability Assessment Schedule II (WHODAS II) (2001) URL http://www.who.int/icidh/whodas/index.html
20. P Ostojic N Damjanov 2006 The Scleroderma Assessment Questionnaire (SAQ). A new self-assessment questionnaire for evaluation of disease status in patients with systemic sclerosis Z Rheumatol 65 168 175 10.1007/s00393-006-0050- 7 1:STN:280:DC%2BD2s3lsFWltQ%3D%3D 16501926
21. PJ Clements JR Seibold DE Furst, et al. 2004 High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned Semin Arthritis Rheum 33 249 263 10.1053/S0049-0172(03)00135-5 1:CAS:528: DC%2BD2cXhtVOks7c%3D 14978663 (Pubitemid 38280824)
22. JL Poole VD Steen 1991 The use of the health assessment questionnaire (HAQ) to determine physical disability in systemic sclerosis Arthritis Care Res 4 27 31 10.1002/art.1790040106 1:STN:280:DC%2BD3M7jslygtA%3D%3D 11188583
23. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee 1980 Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis Rheum 23 581 590 10.1002/art.1780230510
24. G Valentini W Bencivelli S Bombardieri, et al. 2003 European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria Ann Rheum Dis 62 901 903 10.1136/ard.62.9.901 1:STN:280:DC%2BD3svgsVaisg%3D%3D 12922968 (Pubitemid 37026505)
25. PJ Clements 2000 Systemic sclerosis (scleroderma) and related disorders: clinical aspects Baillieres Clin Rheumatol 14 1 16 10.1053/berh.1999.0074 1:STN:280:DC%2BD3cvot1Wrug%3D%3D (Pubitemid 30353021)
26. CT Derk SA Jimenez 2003 Systemic sclerosis: current views of its pathogenesis Autoimmun Rev 2 181 191 10.1016/S1568-9972(03)00005-3 1:CAS:528:DC%2BD3sXmtFWiurg%3D 12848944 (Pubitemid 36798101)
27. CP Denton CM Black 2004 Scleroderma-clinical and pathological advances Best Pract Res Clin Rheumatol 18 271 290 1:CAS:528:DC%2BD2cXkt1Cnsbg%3D 15158741
28. SR Johnson S Carette JV Dunne 2006 Scleroderma: health services utilization from patients' perspective J Rheumatol 33 6 1123 1127 16755658
29. VD Steen TA Medsger Jr TA Osial GL Ziegler AP Shapiro GP Rodnan 1984 Factors predicting the development of renal involvement in progressive systemic sclerosis Am J Med 76 779 786 10.1016/0002-9343(84)90986-0 1:STN:280: DyaL2c3gtVWqtA%3D%3D 6372452
30. VD Steen C Conte GR Owens TA Medsger Jr 1994 Severe restrictive lung disease in systemic sclerosis Arthritis Rheum 37 1283 1289 10.1002/art. 1780370903 1:STN:280:DyaK2M%2Fjt1aguw%3D%3D 7945490 (Pubitemid 24320744)
31. JPA Ioannidis PG Vlachoyiannopoulos A-B Haidich, et al. 2005 Mortality in systemic sclerosis: an international meta-analysis of individual patient data Am J Med 118 2 10 10.1016/j.amjmed.2004.04.031 15639201 (Pubitemid 40082450)
32. VD Steen TA Medsger Jr 2007 Changes in causes of death in systemic sclerosis, 1972-2002 Ann Rheum Dis 66 940 944 10.1136/ard.2006.066068 17329309 (Pubitemid 46999798)
33. S Henness FM Wigley 2007 Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review Curr Opin Rheumatol 19 611 618 10.1097/BOR.0b013e3282f13137 1:CAS:528:DC%2BD2sXhtFWqsrjP 17917543 (Pubitemid 47530883)
34. M Matucci-Cerinic VD Steen DE Furst JR Seibold 2007 Clinical trials in systemic sclerosis: lessons learned and outcomes Arthritis Res Ther 9 Suppl S7 10.1186/ar2191 17767745